REGENERON PHARMACEUTICALS

Regeneron’s stock hits near 52‑week highs thanks to strong Dupixent® and Eylea HD® sales and a growing pipeline, positioning the biotech for continued growth.

Regeneron’s Libtayo receives EMA approval for a streamlined 12‑week to 6‑week dosing schedule, boosting patient adherence and market competitiveness.

Regeneron confirms Pasatru’s 56‑week extension shows zero new HO lesions and reduced flare‑ups, while a new GLP‑1 study preserves lean mass during weight loss.